TNF blockade requires 1,25(OH) 2D 3to control human Th17-mediated synovial inflammation

Annals of the Rheumatic Diseases

Volumn 71, Issue 4, 2012, Pages 606-612

  Van Hamburg, Jan Piet ^a   Asmawidjaja, Patrick S ^a   Davelaar, Nadine ^a   Mus, Adriana M C ^a   Cornelissen, Ferry ^a   Van Leeuwen, Johannes P T M ^a   Hazes, Johanna M W ^a   Dolhain, Radboud J E M ^a   Bakx, Pieter A G M ^b   Colin, Edgar M ^a,c   Lubberts, Erik ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Maasstad Hospital Rotterdam   (Netherlands)

^c ZGT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; CYTOKINE; INTERLEUKIN 17; INTERLEUKIN 6; INTERLEUKIN 8; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE; STROMELYSIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CELL ACTIVITY; CLINICAL ARTICLE; COCULTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE CONTROL; DRUG EFFICACY; DRUG POTENTIATION; ENZYME INHIBITION; ENZYME REPRESSION; ENZYME SYNTHESIS; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; JOINT BIOPSY; MALE; MONOTHERAPY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RECEPTOR BLOCKING; SYNOVITIS; TH17 CELL;

ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; AUTOCRINE COMMUNICATION; BIOPSY; CALCITRIOL; CELLS, CULTURED; COCULTURE TECHNIQUES; CYTOKINES; DRUG COMBINATIONS; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOLOGIC MEMORY; INFLAMMATION MEDIATORS; INTERLEUKIN-17; MALE; MIDDLE AGED; RECEPTORS, CCR6; RECEPTORS, TUMOR NECROSIS FACTOR; SYNOVIAL MEMBRANE; SYNOVITIS; TH17 CELLS; TISSUE CULTURE TECHNIQUES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84857921562     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2011-200424     Document Type: Article

References (44)

1. Annunziato F, Cosmi L, Liotta F, et al. Type 17 T helper cells-origins, features and possible roles in rheumatic disease. Nat Rev Rheumatol 2009;5:325-31.
2. McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol 2007;7:429-42. (Pubitemid 46834849)
3. Isaacs JD. The changing face of rheumatoid arthritis: sustained remission for all? Nat Rev Immunol 2010;10:605-11.
4. Lubberts E. IL-17/Th17 targeting: on the road to prevent chronic destructive arthritis? Cytokine 2008;41:84-91.
5. van den Berg WB, Miossec P. IL-17 as a future therapeutic target for rheumatoid arthritis. Nat Rev Rheumatol 2009;5:549-53.
6. Zhu J, Yamane H, Paul WE. Differentiation of effector CD4 T cell populations (*). Annu Rev Immunol 2010;28:445-89.
7. Acosta-Rodriguez EV, Rivino L, Geginat J, et al. Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat Immunol 2007;8:639-46. (Pubitemid 46785128)
8. Miossec P, Korn T, Kuchroo VK. Interleukin-17 and type 17 helper T cells. N Engl J Med 2009;361:888-98.
9. Lubberts E. Th17 cytokines and arthritis. Semin Immunopathol 2010;32:43-53.
10. Murphy CA, Langrish CL, Chen Y, et al. Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med 2003;198:1951-7. (Pubitemid 38032126)
11. van Hamburg JP, Mus AM, de Bruijn MJ, et al. GATA-3 protects against severe joint inflammation and bone erosion and reduces differentiation of Th17 cells during experimental arthritis. Arthritis Rheum 2009;60:750-9.
12. Nistala K, Moncrieffe H, Newton KR, et al. Interleukin-17-producing T cells are enriched in the joints of children with arthritis, but have a reciprocal relationship to regulatory T cell numbers. Arthritis Rheum 2008;58:875-87. (Pubitemid 351364887)
13. Chabaud M, Durand JM, Buchs N, et al. Human interleukin-17: A T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis Rheum 1999;42:963-70. (Pubitemid 29215007)
14. Kotake S, Udagawa N, Takahashi N, et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 1999;103:1345-52. (Pubitemid 29218305)
15. Raza K, Falciani F, Curnow SJ, et al. Early rheumatoid arthritis is characterized by a distinct and transient synovial fluid cytokine profile of T cell and stromal cell origin. Arthritis Res Ther 2005;7:R784-95.
16. Leipe J, Grunke M, Dechant C, et al. Role of Th17 cells in human autoimmune arthritis. Arthritis Rheum 2010;62:2876-85.
17. van Hamburg JP, Asmawidjaja PS, Davelaar N, et al. Th17 cells, but not Th1 cells, from patients with early rheumatoid arthritis are potent inducers of matrix metalloproteinases and proinflammatory cytokines upon synovial fibroblast interaction, including autocrine interleukin-17A production. Arthritis Rheum 2011;63:73-83.
18. Genovese MC, Van den Bosch F, Roberson SA, et al. LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double-blind, placebo-controlled, proof-of-concept study. Arthritis Rheum 2010;62:929-39.
19. Tang J, Zhou R, Luger D, et al. Calcitriol suppresses antiretinal autoimmunity through inhibitory effects on the Th17 effector response. J Immunol 2009;182:4624-32.
20. Penna G, Amuchastegui S, Cossetti C, et al. Treatment of experimental autoimmune prostatitis in nonobese diabetic mice by the vitamin D receptor agonist elocalcitol. J Immunol 2006;177:8504-11. (Pubitemid 44895295)
21. Gauzzi MC, Purificato C, Donato K, et al. Suppressive effect of 1alpha,25-dihydroxyvitamin D3 on type I IFN-mediated monocyte differentiation into dendritic cells: impairment of functional activities and chemotaxis. J Immunol 2005;174:270-6. (Pubitemid 40007413)
22. Mathieu C, van Etten E, Decallonne B, et al. Vitamin D and 1,25-dihydroxyvitamin D3 as modulators in the immune system. J Steroid Biochem Mol Biol 2004;89-90:449-52. (Pubitemid 38844328)
23. D'Ambrosio D, Cippitelli M, Cocciolo MG, et al. Inhibition of IL-12 production by 1,25-dihydroxyvitamin D3. Involvement of NF-kappaB downregulation in transcriptional repression of the p40 gene. J Clin Invest 1998;101:252-62. (Pubitemid 28058925)
24. Mora JR, Iwata M, von Andrian UH. Vitamin effects on the immune system: vitamins A and D take centre stage. Nat Rev Immunol 2008;8:685-98.
25. Chang SH, Chung Y, Dong C. Vitamin D suppresses Th17 cytokine production by inducing C/EBP homologous protein (CHOP) expression. J Biol Chem 2010;285:38751-5.
26. von Essen MR, Kongsbak M, Schjerling P, et al. Vitamin D controls T cell antigen receptor signaling and activation of human T cells. Nat Immunol 2010;11:344-9.
27. Colin EM, Asmawidjaja PS, van Hamburg JP, et al. 1,25-dihydroxyvitamin D3 modulates Th17 polarization and interleukin-22 expression by memory T cells from patients with early rheumatoid arthritis. Arthritis Rheum 2010;62:132-42.
28. Borgogni E, Sarchielli E, Sottili M, et al. Elocalcitol inhibits inflammatory responses in human thyroid cells and T cells. Endocrinology 2008;149:3626-34. (Pubitemid 351919622)
29. Rausch-Fan X, Leutmezer F, Willheim M, et al. Regulation of cytokine production in human peripheral blood mononuclear cells and allergen-specific th cell clones by 1alpha,25-dihydroxyvitamin D3. Int Arch Allergy Immunol 2002;128:33-41. (Pubitemid 34621664)
30. Correale J, Ysrraelit MC, Gaitán MI. Immunomodulatory effects of vitamin D in multiple sclerosis. Brain 2009;132(Pt 5):1146-60.
31. Boonstra A, Barrat FJ, Crain C, et al. 1alpha,25-Dihydroxyvitamin d3 has a direct effect on naive CD4(+) T cells to enhance the development of Th2 cells. J Immunol 2001;167:4974-80. (Pubitemid 33009728)
32. Spach KM, Nashold FE, Dittel BN, et al. IL-10 signaling is essential for 1,25-dihydroxyvitamin D3-mediated inhibition of experimental autoimmune encephalomyelitis. J Immunol 2006;177:6030-7. (Pubitemid 44628817)
33. Cantorna MT, Hayes CE, DeLuca HF. 1,25-Dihydroxycholecalciferol inhibits the progression of arthritis in murine models of human arthritis. J Nutr 1998;128:68-72. (Pubitemid 28087178)
34. Rossini M, Maddali Bongi S, La Montagna G, et al. Vitamin D deficiency in rheumatoid arthritis: prevalence, determinants and associations with disease activity and disability. Arthritis Res Ther 2010;12:R216.
35. Lee YH, Bae SC, Choi SJ, et al. Associations between vitamin D receptor polymorphisms and susceptibility to rheumatoid arthritis and systemic lupus erythematosus: a meta-analysis. Mol Biol Rep 2011;38:3643-51.
36. Cutolo M. Vitamin D and autoimmune rheumatic diseases. Rheumatology (Oxford) 2009;48:210-12.
37. Andjelkovic Z, Vojinovic J, Pejnovic N, et al. Disease modifying and immunomodulatory effects of high dose 1 alpha (OH) D3 in rheumatoid arthritis patients. Clin Exp Rheumatol 1999;17:453-6. (Pubitemid 29343630)
38. Miossec P. Interleukin-17 in rheumatoid arthritis: if T cells were to contribute to inflammation and destruction through synergy. Arthritis Rheum 2003;48:594-601. (Pubitemid 36301993)
39. Tetlow LC, Woolley DE. The effects of 1 alpha,25-dihydroxyvitamin D(3) on matrix metalloproteinase and prostaglandin E(2) production by cells of the rheumatoid lesion. Arthritis Res 1999;1:63-70. (Pubitemid 32223674)
40. Kirkham BW, Lassere MN, Edmonds JP, et al. Synovial membrane cytokine expression is predictive of joint damage progression in rheumatoid arthritis: a two-year prospective study (the DAMAGE study cohort). Arthritis Rheum 2006;54:1122-31. (Pubitemid 43672925)
41. Klareskog L, van der Heijde D, de Jager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004;363:675-81. (Pubitemid 38296553)
42. Vieth R. Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety. Am J Clin Nutr 1999;69:842-56. (Pubitemid 29205056)
43. Cutolo M, Plebani M, Shoenfeld Y, et al. Vitamin D endocrine system and the immune response in rheumatic diseases. Vitam Horm 2011;86:327-51.
44. Nelson CD, Reinhardt TA, Beitz DC, et al. In vivo activation of the intracrine vitamin D pathway in innate immune cells and mammary tissue during a bacterial infection. PLoS ONE 2010;5:e15469.